BullFrog AI (BFRG) stock jumped 106% after announcing a drug discovery deal with a top-5 pharma firm targeting major ...

BullFrog AI (BFRG) stock surged 101% after securing a commercial partnership with a top 5 pharma company for depression drug target identification.

LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately ...

Background Alcohol use disorder and treatment-resistant depression (TRD) often co-occur, presenting a major clinical challenge with limited effective treatments. However, ketamine produces rapid ...

Neuronetics, Inc. 2026 turnaround? New CEO Dan Reuvers and the Greenbrook deal drove revenue growth—see key valuation and ...

Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains ...

Cybin Inc (NASDAQ:HELP) is among the best psychedelic stocks to buy in 2026. Toronto, Canada-based Cybin Inc. is also known ...

Reported positive results from potentially registrational Phase 2 trial ofLB-102 in schizophrenia Advanced LB-102 into late-stage development in multiple indications with initiation ofa pivotal Phase ...

Share on Pinterest Menopause may be associated with the onset of new mental health conditions, yet many females remain unaware of the connection. Image Credit: mapodile/Getty Images A new position ...

Nexstim's NBS System 6 gains FDA clearance for treatment of Obsessive Compulsive Disorder (OCD) Nexstim Plc ("Nexstim" or "Company") announces the ...

Imagine a severely depressed woman—let’s call her Amber—who just arrived at her therapist’s office. She is curious about receiving her first dose of psilocybin in a Phase 3 clinical study. Psilocybin ...